Prometheus Biosciences, Inc. clinical trials
Acquired by Merck & Co., Inc, Jun 16, 2023 · source ↗
The registry lists 6 studies whose lead sponsor is Prometheus Biosciences, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 22, 2026.
- 6studies on the registry
- 0open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc
- 6
- First submitted after Prometheus Biosciences, Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Prometheus Biosciences, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 5
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 20
- 21
- 322
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Merck & Co., Inc studies →
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)Active, not recruitingNCT05270668Phase 2
Sponsor listed in the registry: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)CompletedNCT04996797Phase 2
Sponsor listed in the registry: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc
- A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)CompletedNCT05013905Phase 2
Sponsor listed in the registry: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc
- A Study of PRA052 in Healthy VolunteersCompletedNCT05603182Phase 1
Sponsor listed in the registry: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc
- A Study of PRA023 in Healthy VolunteersCompletedNCT04676178Phase 1
Sponsor listed in the registry: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc
- Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023CompletedNCT05354349Phase 1
Sponsor listed in the registry: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Prometheus Biosciences, Inc. became part of Merck & Co., Inc